RS58734B1 - Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor - Google Patents

Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor

Info

Publication number
RS58734B1
RS58734B1 RS20190351A RSP20190351A RS58734B1 RS 58734 B1 RS58734 B1 RS 58734B1 RS 20190351 A RS20190351 A RS 20190351A RS P20190351 A RSP20190351 A RS P20190351A RS 58734 B1 RS58734 B1 RS 58734B1
Authority
RS
Serbia
Prior art keywords
compound
inhibitor
combination
cetuximab
raf
Prior art date
Application number
RS20190351A
Other languages
English (en)
Serbian (sr)
Inventor
Giordano Caponigro
Darrin Stuart
Parseval Laure Moutouh-De
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58734(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of RS58734B1 publication Critical patent/RS58734B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RS20190351A 2012-08-07 2013-08-05 Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor RS58734B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07
PCT/US2013/053619 WO2014025688A1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EP13748243.6A EP2882440B1 (en) 2012-08-07 2013-08-05 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor

Publications (1)

Publication Number Publication Date
RS58734B1 true RS58734B1 (sr) 2019-06-28

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20190351A RS58734B1 (sr) 2012-08-07 2013-08-05 Farmaceutske kombinacije koje obuhvataju b-raf inhibitor, egfr inhibitor i opciono pi3k-alfa inhibitor

Country Status (39)

Country Link
US (1) US9474754B2 (forum.php)
EP (2) EP2882440B1 (forum.php)
JP (3) JP6342396B2 (forum.php)
KR (1) KR102112885B1 (forum.php)
CN (1) CN104519887B (forum.php)
AR (1) AR092045A1 (forum.php)
AU (1) AU2013299841B8 (forum.php)
CA (1) CA2879548C (forum.php)
CL (1) CL2015000294A1 (forum.php)
CO (1) CO7200273A2 (forum.php)
CY (1) CY1122143T1 (forum.php)
DK (1) DK2882440T3 (forum.php)
EA (1) EA028420B1 (forum.php)
EC (1) ECSP15008695A (forum.php)
ES (1) ES2717911T3 (forum.php)
GT (1) GT201500025A (forum.php)
HK (1) HK1211831A1 (forum.php)
HR (1) HRP20190537T1 (forum.php)
HU (1) HUE042877T2 (forum.php)
IL (1) IL236934B (forum.php)
IN (1) IN2015DN00450A (forum.php)
JO (1) JOP20130236B1 (forum.php)
LT (1) LT2882440T (forum.php)
MA (1) MA37829A1 (forum.php)
MX (1) MX359403B (forum.php)
MY (1) MY176031A (forum.php)
NZ (1) NZ703940A (forum.php)
PE (2) PE20191655A1 (forum.php)
PH (1) PH12015500246A1 (forum.php)
PL (1) PL2882440T3 (forum.php)
PT (1) PT2882440T (forum.php)
RS (1) RS58734B1 (forum.php)
SG (1) SG11201500321YA (forum.php)
SI (1) SI2882440T1 (forum.php)
TN (1) TN2015000027A1 (forum.php)
TR (1) TR201904980T4 (forum.php)
TW (1) TWI607754B (forum.php)
UA (1) UA115786C2 (forum.php)
WO (1) WO2014025688A1 (forum.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20191655A1 (es) * 2012-08-07 2019-11-07 Novartis Ag Combinaciones farmaceuticas
KR102258698B1 (ko) 2013-03-21 2021-06-01 노파르티스 아게 B-Raf 억제제와 제2 억제제를 포함하는 조합 요법
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
JP6704861B2 (ja) * 2014-06-16 2020-06-03 ワールドワイド・イノベイティブ・ネットワークWorldwide Innovative Network 癌処置のための個別化三剤治療を選択するための方法
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
CN107921037A (zh) * 2015-08-28 2018-04-17 诺华股份有限公司 含pi3k抑制剂alpelisib和b‑raf抑制剂达拉菲尼的药物组合;该组合在治疗或预防癌症中的应用
WO2017037578A2 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination therapy
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
DK3463345T3 (da) * 2016-06-03 2023-01-09 Array Biopharma Inc Farmaceutiske kombinationer
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
PL3618875T3 (pl) 2017-05-02 2023-10-23 Novartis Ag Terapia skojarzona obejmująca inhibitor raf i trametynib
MX2020001254A (es) * 2017-08-03 2020-03-20 Novartis Ag Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
TW202444718A (zh) * 2019-01-25 2024-11-16 英屬開曼群島商百濟神州有限公司 作為b-raf激酶二聚體抑制劑之化合物及其製備方法
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
EP3969449B1 (en) 2019-05-13 2025-02-12 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JPWO2023145530A1 (forum.php) * 2022-01-27 2023-08-03
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd Int Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
TW202421133A (zh) * 2022-09-26 2024-06-01 美商馬布可爾公司 用於治療癌症的b-raf抑制劑和抗egfr抗體之組合
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR101626435B1 (ko) 2007-04-10 2016-06-01 엑셀리시스, 인코포레이티드 Pi3k 알파의 피리도피리미디논 억제제를 이용한 암 치료 방법
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
RU2553379C2 (ru) * 2009-08-24 2015-06-10 Дженентек, Инк. ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
JP2013507442A (ja) * 2009-10-12 2013-03-04 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 組合せ
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
BR112013009624A2 (pt) * 2010-11-08 2016-07-12 Novartis Ag uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr
CA2855245A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center Treatment of ovarian cancer with 2-amino-4h-naphtho[1,2-b]pyran-3-carbonitriles
WO2013070996A1 (en) * 2011-11-11 2013-05-16 Novartis Ag Method of treating a proliferative disease
PE20191655A1 (es) * 2012-08-07 2019-11-07 Novartis Ag Combinaciones farmaceuticas

Also Published As

Publication number Publication date
PH12015500246B1 (en) 2015-03-30
TWI607754B (zh) 2017-12-11
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
TN2015000027A1 (en) 2016-06-29
AU2013299841B2 (en) 2016-11-24
JP6342396B2 (ja) 2018-06-13
LT2882440T (lt) 2019-04-25
EA201590332A1 (ru) 2015-06-30
CL2015000294A1 (es) 2015-05-08
JP2020019780A (ja) 2020-02-06
WO2014025688A1 (en) 2014-02-13
PH12015500246A1 (en) 2015-03-30
AU2013299841A1 (en) 2015-02-12
HUE042877T2 (hu) 2019-07-29
ECSP15008695A (es) 2019-03-29
JP6974669B2 (ja) 2021-12-01
US20150265616A1 (en) 2015-09-24
TR201904980T4 (tr) 2019-05-21
IL236934B (en) 2018-11-29
CN104519887A (zh) 2015-04-15
EP2882440A1 (en) 2015-06-17
EA028420B1 (ru) 2017-11-30
MY176031A (en) 2020-07-22
AU2013299841A8 (en) 2017-01-05
SG11201500321YA (en) 2015-04-29
US9474754B2 (en) 2016-10-25
HRP20190537T1 (hr) 2019-06-28
TW201410247A (zh) 2014-03-16
CY1122143T1 (el) 2020-11-25
HK1204976A1 (en) 2015-12-11
PE20191655A1 (es) 2019-11-07
UA115786C2 (uk) 2017-12-26
CN104519887B (zh) 2017-06-27
JP6595024B2 (ja) 2019-10-23
CO7200273A2 (es) 2015-02-27
ES2717911T3 (es) 2019-06-26
JP2018109022A (ja) 2018-07-12
BR112015002384A2 (pt) 2017-07-04
MX359403B (es) 2018-09-26
IN2015DN00450A (forum.php) 2015-06-26
GT201500025A (es) 2017-09-28
KR102112885B1 (ko) 2020-05-19
AU2013299841B8 (en) 2017-01-05
MA37829A1 (fr) 2017-01-31
DK2882440T3 (da) 2019-05-06
PE20150673A1 (es) 2015-05-20
NZ703940A (en) 2018-04-27
KR20150040905A (ko) 2015-04-15
PL2882440T3 (pl) 2019-07-31
EP2882440B1 (en) 2019-02-27
BR112015002384A8 (pt) 2023-01-31
PT2882440T (pt) 2019-04-23
JOP20130236B1 (ar) 2021-08-17
HK1211831A1 (zh) 2016-06-03
SI2882440T1 (sl) 2019-05-31
JP2015524472A (ja) 2015-08-24
MX2015001732A (es) 2015-06-03
AR092045A1 (es) 2015-03-18
CA2879548C (en) 2020-07-21

Similar Documents

Publication Publication Date Title
JP6595024B2 (ja) B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬
JP6742391B2 (ja) 併用療法
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK40051622A (en) Combination therapy comprising a b-raf inhibitor and a second inhibitor
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos
JP2019131559A (ja) 頭頚部がんの処置または予防において使用されるpi3キナーゼ阻害剤とパクリタキセルの組合せ
EA040191B1 (ru) Комбинированная терапия